FDA Peptide Regulatory Status (United States)
A comprehensive guide to the regulatory status of peptides under the U.S. Food and Drug Administration (FDA), including the landmark 2026 reclassification that restored 14 peptides to compoundable status.
FDA Regulatory Categories
FDA Approved
Peptides that have completed full FDA approval and are available as branded prescription drugs. Examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). These are manufactured by pharmaceutical companies and prescribed through standard channels.
Category 1 -- Compoundable
Peptides on the FDA's Category 1 bulk drug substance list, eligible for use by licensed compounding pharmacies under Section 503A/503B of the Federal Food, Drug, and Cosmetic Act. These require a prescription from a licensed provider. Compounding pharmacies can produce custom preparations of these peptides.
Category 2 -- Not Compoundable
Peptides that the FDA has placed on the Category 2 list, meaning compounding pharmacies are prohibited from producing them. This includes peptides deemed to have insufficient safety data or unacceptable risk profiles. Possession may be restricted.
Research Only
Peptides that are not approved for human use and may only be legally purchased for in-vitro research purposes. They are typically sold by chemical supply companies labeled "not for human consumption." Clinical use falls into a regulatory gray area.
Pipeline (Clinical Trials)
Peptides currently in FDA clinical trials (Phase 1, 2, or 3). These are not yet available outside of clinical trial participation. If trials succeed, they may receive FDA approval.
OTC / Supplement
Peptides available without a prescription, either as over-the-counter products or dietary supplements. These include topical cosmetic peptides (like Argireline) and oral supplements. The FDA regulates these under different frameworks than prescription drugs.
2026 FDA Reclassification: 14 Peptides Restored to Category 1
In early 2026, the FDA issued a landmark reclassification that moved 14 peptides from restricted/gray-area status back to Category 1, making them eligible for production by licensed compounding pharmacies with a valid prescription. This decision followed extensive public comment periods, pressure from medical practitioners and patient advocacy groups, and a review of safety data accumulated over decades of clinical use.
The reclassification acknowledged that these peptides have established safety profiles and fill legitimate medical needs that may not be met by commercially available FDA-approved drugs. It does not constitute FDA approval -- these peptides are compoundable under Section 503A/503B, meaning they must be prepared by a licensed compounding pharmacy and dispensed with a prescription.
All Peptides: FDA Regulatory Status
| Peptide | FDA Status |
|---|---|
| Semaglutide Ozempic, Wegovy, Rybelsus | FDA Approved |
| Tirzepatide Mounjaro, Zepbound | FDA Approved |
| PT-141 Vyleesi | FDA Approved |
| Liraglutide Victoza, Saxenda | FDA Approved |
| Tesamorelin Egrifta | FDA Approved |
| Oxytocin Pitocin, Syntocinon | FDA Approved |
| BPC-157 | Compoundable (Rx) |
| TB-500 | Compoundable (Rx) |
| GHK-Cu | Compoundable (Rx) |
| Ipamorelin | Compoundable (Rx) |
| CJC-1295 | Compoundable (Rx) |
| Sermorelin Geref | Compoundable (Rx) |
| AOD-9604 | Compoundable (Rx) |
| Semax | Compoundable (Rx) |
| Selank | Compoundable (Rx) |
| Epitalon | Compoundable (Rx) |
| MOTS-c | Compoundable (Rx) |
| Thymosin Alpha-1 Zadaxin | Compoundable (Rx) |
| KPV | Compoundable (Rx) |
| DSIP | Compoundable (Rx) |
| Kisspeptin-10 | Compoundable (Rx) |
| Argireline Argireline | Over-the-Counter |
| Matrixyl 3000 Matrixyl 3000 | Over-the-Counter |
| Melanotan II | Research Only |
| LL-37 | Research Only |
| GHRP-2 | Research Only |
| GHRP-6 | Research Only |
| FOXO4-DRI | Research Only |
| Dihexa | Research Only |
| Humanin | Research Only |
| Retatrutide | In Clinical Trials |
| SS-31 | In Clinical Trials |
Important Regulatory Notes
Compounding vs. FDA approval:A peptide being "compoundable" under Category 1 is not the same as FDA approval. Compounded peptides have not undergone the full New Drug Application (NDA) process. They are produced by licensed pharmacies under Section 503A (patient-specific) or Section 503B (outsourcing facility) regulations.
State-level variation: Individual states may impose additional restrictions on compounding pharmacies or specific substances. The FDA framework sets the federal baseline, but state pharmacy boards may have stricter rules.
Enforcement trends:The FDA has increased enforcement actions against companies selling peptides labeled "for research only" when marketing suggests human use. The 2026 reclassification was partly intended to create a clearer legal pathway for peptides with established safety profiles.
Import restrictions: Importing peptides from overseas for personal use is technically illegal under FDA regulations, though enforcement has been inconsistent. The reclassification of Category 1 peptides provides a legal domestic alternative through compounding pharmacies.
Last updated: April 2026. This page reflects the FDA regulatory landscape as of early 2026, including the Category 1 reclassification. Regulatory status can change -- always verify current status with a licensed healthcare provider or legal counsel.